Novartis
NVS
1,390 hedge funds and large institutions have $16.2B invested in Novartis in 2025 Q2 according to their latest regulatory filings, with 120 funds opening new positions, 494 increasing their positions, 479 reducing their positions, and 76 closing their positions.
58% more first-time investments, than exits
New positions opened: 120 | Existing positions closed: 76
21% more funds holding in top 10
Funds holding in top 10: 14 → 17 (+3)
2% more funds holding
Funds holding: 1,363 → 1,390 (+27)
3% more repeat investments, than reductions
Existing positions increased: 494 | Existing positions reduced: 479
0.22% less ownership
Funds ownership: 6.98% → 6.76% (-0.22%)
19% less call options, than puts
Call options by funds: $269M | Put options by funds: $331M
32% less capital inflows, than outflows
Capital inflows: $919M | Capital outflows: $1.34B
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$56.8M |
| 2 |
Optiver Holding
Amsterdam,
Netherlands
|
+$53.4M |
| 3 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$52.9M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$51.2M |
| 5 |
Millennium Management
New York
|
+$47M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CIBC World Market
Toronto,
Ontario, Canada
|
-$192M |
| 2 |
Dodge & Cox
San Francisco,
California
|
-$132M |
| 3 |
Goldman Sachs
New York
|
-$126M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$120M |
| 5 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$102M |
NVS Hedge Fund Activity: Q2 2025 in Review
1,390 of the 7,630 institutional investors tracked by Wall St. Rank reported a position in Novartis (NVS) for Q2 2025, worth a combined $16.2B — up 5.1% from $15.4B a quarter earlier.
Buyers outnumbered sellers: 120 funds opened new NVS positions and 76 closed out — a net gain of 44 holders — while 494 added to existing stakes and 479 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $56.8M. The largest seller was CIBC World Market, cutting an estimated $192M.
- 1,390 institutional investors held Novartis (NVS) as of Q2 2025, up from 1,363 in Q1 2025.
- Funds reported $16.2B of Novartis stock for Q2 2025, up 5.1% quarter-over-quarter.
- 120 funds opened new Novartis positions in Q2 2025 and 76 closed out, a net change of +44 holders.
- The largest Novartis buyer in Q2 2025 was Morgan Stanley, an estimated $56.8M added.
- The largest Novartis seller in Q2 2025 was CIBC World Market, an estimated $192M sold.
Based on aggregated 13F filings for Q2 2025.